Clinical Trial Update: Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial

View source ↗

Summary

A prospective observational KiRi-Trial investigates kidney function and risk factors in patients with metastatic castration-resistant prostate cancer undergoing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Kidney Disease
• Radiation Nephropathy

Drugs mentioned

• Lutetium-177 PSMA-617 (Pluvicto) (lutetium-177 PSMA-617)

Snippet

Sponsor: Hannah Schaefer | Conditions: Kidney Disease, Radiation Nephropathy | Status: RECRUITING